Small early human studies show sustained GH and IGF-I elevation after CJC-1295 with DAC, establishing endocrine target engagement but not body-composition, recovery or anti-ageing efficacy.
Regulatory status
Not FDA-approved; FDA lists CJC-1295 among substances with significant safety concerns in compounding.
Main limitations
Meaningful fat-loss, muscle-gain, recovery or anti-ageing benefit, long-term safety or equivalence of marketplace formulations.
Safety
Endocrine effects are expected; FDA has reported serious adverse events including increased heart rate and systemic vasodilatory reactions in available CJC-1295 data.
i
Small early human studies show sustained GH and IGF-I elevation after CJC-1295 with DAC, establishing endocrine target engagement but not body-composition, recovery or anti-ageing efficacy.
What the evidence actually supports
✓Hormone elevation is not the same endpoint as a meaningful health or body-composition benefit.
✓Hormone elevation is not a clinical lifestyle outcome.
✓Pair original Phase I pharmacology with current regulator safety interpretation.
What is not established / key limitations
×No controlled evidence in these studies for anti-ageing, fat loss, muscle gain or injury recovery.
×Clinically meaningful physique/recovery outcomes were not established.
×Long-term safety, repeated exposure and exact substance identity remain uncertain.
Selected study & evidence records
CJC-1295 increases GH and IGF-I in healthy adults
2006 · Two randomized placebo-controlled dose-escalation studies
GH increased approximately 2-10-fold for at least 6 days and IGF-I about 1.5-3-fold for 9-11 days; estimated half-life 5.8-8.1 days.
FDA states available clinical data are limited and has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction.
Endocrine effects are expected; FDA has reported serious adverse events including increased heart rate and systemic vasodilatory reactions in available CJC-1295 data.
FDA reports limited clinical data and serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction; long-term safety and immunogenicity remain inadequately characterized.
Technical details
Mechanism / biologyGHRH analogue with drug-affinity-complex technology that prolongs exposure and stimulates GH/IGF-1 secretion.
Route / formulation boundaryCJC-1295 with DAC is not interchangeable with informal 'CJC without DAC' products.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Dosing evidence statusVerified dosing evidence added. Published human pharmacology regimen. See dosing_evidence records for route, regimen, population, duration and source.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
